A Randomized Placebo Controlled Phase II Trial of Afatinib (BIBW2992) as Adjuvant Therapy Following Chemoradiation in Patients With Head and Neck Squamous Cell Carcinoma at High Risk of Recurrence
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 12 Jan 2018
At a glance
- Drugs Afatinib (Primary)
- Indications Head and neck cancer; Hypopharyngeal cancer; Orofacial cancer; Oropharyngeal cancer
- Focus Therapeutic Use
- 12 Dec 2017 Planned End Date changed from 1 Jan 2020 to 1 Dec 2020.
- 12 Dec 2017 Status changed to active, no longer recruiting.
- 11 Sep 2015 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov record.